Original paperAn open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens☆
References (13)
- et al.
Methodology of antiemetic trials: a review
Ann Oncol
(1991) - et al.
5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy. A randomised study
Eur J Cancer
(1993) - et al.
A double-blind, randomised, crossover comparison of Granisetron and Ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference
Eur J Cancer
(1994) - et al.
Efficacy of Ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting
N Engl J Med
(1990) - et al.
Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis
N Engl J Med
(1990) Efficacy and safety of Granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study
Eur J Cancer
(1990)
There are more references available in the full text version of this article.
Cited by (26)
A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation
1999, Biology of Blood and Marrow Transplantation5-HT<inf>3</inf> receptor antagonists: Differences and similarities
1997, European Journal of Cancer Part AAntiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
2021, Cochrane Database of Systematic Reviews
- ☆
Presented in part at the Annual ASCO meeting 1994.
Copyright © 1996 Published by Elsevier Ltd.